Effect of Two Different Superstrate Layers on Bismuth titanate (BiT) array antennas

The microwave industry has shown increasing interest in electronic ceramic material (ECM) due to its advantages, such as light weight, low cost, low loss, and high dielectric strength. In this paper, simple antennas covered by superstrate layers for 2.30 GHz to 2.50 GHz are proposed. The antennas are compact and have the capability of producing high performance in terms of gain, directivity, and radiation efficiency. Bismuth titanate with high dielectric constant of 21, was utilized as the ECM, while the superstrate layers chosen included a split ring resonator and dielectric material. The superstrate layers were designed for some improvement in the performance of directivity, gain, and return loss. The proposed antennas were simulated and fabricated. The results obtained were small antennas that possess high gain and high directivity with 3606, omni-directional signal transmission that resonant types of conventional dipole antenna cannot achieve. The gain of the antenna with the superstrate layer was enhanced by about 1 dBi over the antenna without a superstrate layer at 2.40 GHz

Study of 5.8 GHz Band-Stop Frequency Selective Surface (FSS)

This paper presents the study of 5.8 GHz frequency selective surface (FSS) acts as a band stop to eliminate unwanted radiation signal at 5.8GHz. The FSS was designed using computer simulation technology (CST) Microwave Studio software. The paper shows the comparison of square loop, octagon loop and hexagon loop of Band stop FSS (BSFSS) performance at 5.8 GHz. Besides, the BSFSS design using four different type of dielectric substrate such as FR-4, TLY-5, Roger RT5870 and Roger RT5880 were compared. The results obviously show that the Rogers RY5880 has the attenuation -44.72 dB.  The fabricated FSS were measured by using free space technique with two horn antennas connected to performance network analyzer (PNA). The measured and simulated results were compared. The results show that the square loop FSS structure have the better attenuation -26.76 dB (simulated) and -38.34 dB (measured) at 5.8 GHz

Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: A multi-center randomized clinical trial

Introduction: Because of ongoing controversy, renal and vital outcomes are compared between systemically administered unfractionated heparin and regional anticoagulation with citrate-buffered replacement solution in predilution mode, during continuous venovenous hemofiltration (CVVH) in critically ill patients with acute kidney injury (AKI).Methods: In this multi-center randomized controlled trial, patients admitted to the intensive care unit requiring CVVH and meeting inclusion criteria, were randomly assigned to citrate or heparin. Primary endpoints were mortality and renal outcome in intention-to-treat analysis. Secondary endpoints were safety and efficacy. Safety was defined as absence of any adverse event necessitating discontinuation of the assigned anticoagulant. For efficacy, among other parameters, survival times of the first hemofilter were studied.Results: Of the 139 patients enrolled, 66 were randomized to citrate and 73 to heparin. Mortality rates at 28 and 90 days did not differ between groups: 22/66 (33%) of citrate-treated patients died versus 25/72 (35%) of heparin-treated patients at 28 days, and 27/65 (42%) of citrate-treated patients died versus 29/69 (42%) of heparin-treated patients at 90 days (P = 1.00 for both). Renal outcome, i.e. independency of renal replacement therapy 28 days after initiation of CVVH in surviving patients, did not differ between groups: 29/43 (67%) in the citrate-treated patients versus 33/47 (70%) in heparin-treated patients (P = 0.82). Heparin was discontinued in 24/73 (33%) of patients whereas citrate was discontinued in 5/66 (8%) of patients (P < 0.001). Filter survival times were superior for citrate (median 46 versus 32 hour

Simulation Analysis and Electromagnetic Dosimetry of Patch Antenna on Hugo Voxel Model

The off-body, on-body simulation analysis and electromagnetic dosimetry of a simple structure patch antenna operating in 2.45 GHz ISM band is presented. The antenna design is based on conventional structure with flexible substrate features and copper as the conductive plane. The simulation analysis was performed in CST Microwave Studio. Anatomic simulation using HUGO voxel model was used for on-body simulation and electromagnetic dosimetry. For off-body analysis, the antenna resonates at 2.45 GHz with S11 parameter of -32.56 dB and radiates unidirectionally with efficiency of 91.96 %. It was found that the presence of human lossy tissues and organs caused frequency detuning of 50.4-51.5 MHz and radiation efficiency degradation of 7.93 % to 13.78 %. The electromagnetic dosimetry on specific absorption rate (SAR) exposure of the antenna when it is mounted over averaged 10 g of tissues for chest, back, abdomen, arm and thigh was well below the IEEE Std. C95.3 limit. The maximum and minimum SAR was found when the antenna was placed on the back (0.332 W/kg) and arm (0.121 W/kg) respectively on the human body. Varying the distance from 0-20 mm of the antenna from the human body reduces the SAR exposure to the human body

Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial

INTRODUCTION: Because of ongoing controversy, renal and vital outcomes are compared between systemically administered unfractionated heparin and regional anticoagulation with citrate-buffered replacement solution in predilution mode, during continuous venovenous hemofiltration (CVVH) in critically ill patients with acute kidney injury (AKI). METHODS: In this multi-center randomized controlled trial, patients admitted to the intensive care unit requiring CVVH and meeting inclusion criteria, were randomly assigned to citrate or heparin. Primary endpoints were mortality and renal outcome in intention-to-treat analysis. Secondary endpoints were safety and efficacy. Safety was defined as absence of any adverse event necessitating discontinuation of the assigned anticoagulant. For efficacy, among other parameters, survival times of the first hemofilter were studied. RESULTS: Of the 139 patients enrolled, 66 were randomized to citrate and 73 to heparin. Mortality rates at 28 and 90 days did not differ between groups: 22/66 (33%) of citrate-treated patients died versus 25/72 (35%) of heparin-treated patients at 28 days, and 27/65 (42%) of citrate-treated patients died versus 29/69 (42%) of heparin-treated patients at 90 days (P = 1.00 for both). Renal outcome, i.e. independency of renal replacement therapy 28 days after initiation of CVVH in surviving patients, did not differ between groups: 29/43 (67%) in the citrate-treated patients versus 33/47 (70%) in heparin-treated patients (P = 0.82). Heparin was discontinued in 24/73 (33%) of patients whereas citrate was discontinued in 5/66 (8%) of patients (P < 0.001). Filter survival times were superior for citrate (median 46 versus 32 hours, P = 0.02), as were the number of filters used (P = 0.002) and the off time within 72 hours (P = 0.002). The costs during the first 72 hours of prescribed CVVH were lower in citrate-based CVVH. CONCLUSIONS: Renal outcome and patient mortality were similar for citrate and heparin anticoagulation during CVVH in the critically ill patient with AKI. However, citrate was superior in terms of safety, efficacy and costs. TRIAL REGISTRATION: Clinicaltrials.gov NCT00209378. Registered 13(th) September 2005. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-014-0472-6) contains supplementary material, which is available to authorized users